ApiFix

Focus: ApiFix is a public Israeli medical device company specializing in minimally invasive scoliosis correction through its MID-C System for adolescent idiopathic scoliosis. The company operates as a focused device manufacturer with a niche but significant orthopedic market.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About ApiFix

AI assessmentNot Hiring

No open roles listed right now. Follow ApiFix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

MID-C System

Adolescent Idiopathic Scoliosis

Growth

Core commercial asset with 7 active clinical trials generating real-world evidence to support market adoption and reimbursement positioning.

Pipeline & Clinical Trials

Help build intelligence for ApiFix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity upside potential and established governance infrastructure absent in pre-revenue startups
Focused single-product strategy in high-unmet-need pediatric orthopedic space allows deep specialization and ownership
Device-based approach de-risks regulatory pathway compared to traditional drug development with 7 active trials generating clinical evidence

Watch Out For

Zero active job openings signal potential hiring freeze, organizational consolidation, or minimal growth phase
Limited pipeline diversity with only one program (MID-C System) creates single-product dependency and vulnerability to competitive threats or market saturation
Data gaps on financials, R&D intensity, and cash position prevent assessment of runway and investment in innovation

Generated by Claude from ApiFix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MID-C

Scoliosis

N/A

Clinical Trials (1)

NCT03519321Minimal Invasive Deformity Correction (MID-C) System for Early Onset Scoliosis

N/A

Feasibility Study of MID-C for AIS

Adolescent Idiopathic Scoliosis (AIS)

N/A

Clinical Trials (1)

NCT03071445Feasibility Study of MID-C for AIS

N/A

MID-C

Adolescent Idiopathic Scoliosis (AIS)

N/A

Clinical Trials (1)

NCT03071471Feasibility Evaluation Study of the MID-C Device

N/A

SDS

Early-Onset Scoliosis Deformity of Spine (Disorder)

N/A

Clinical Trials (1)

NCT04003233Limited-efficacy Testing of Spring Distraction System (SDS) and Unilateral One-way Rod (MID-C) for Early Onset Scoliosis

N/A

Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in A

Adolescent Idiopathic Scoliosis (AIS)

N/A

Clinical Trials (1)

NCT02200302Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)

N/A

MID-C System

Adolescent Idiopathic Scoliosis

N/A

Clinical Trials (2)

NCT04296903Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)

N/A

NCT04684927PMS Evaluation of Safety and Efficacy of the MID-C System 5 Years Post-implantation in AIS

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo